Rhododendrol

Other Names

(R)-(-)-Rhododendrol(R)-4-(3-Hydroxybutyl)phenol(R)-Frambinol(S)-(+)-Rhododendrol(S)-Frambinol(αR)-4-Hydroxy-α-methylbenzenepropanol4-(3-Hydroxybutyl)phenol4-(4-Hydroxyphenyl)-2-butanol4-(p-Hydroxyphenyl)butan-2-ol4-HPB4-Hydroxy-α-methyl-benzenepropanol4-[(3R)-3-Hydroxybutyl]phenol4-[(3S)-3-Hydroxybutyl]phenolBenzenepropanol, 4-hydroxy-α-methyl-Benzenepropanol, 4-hydroxy-α-methyl-, (R)-Benzenepropanol, 4-hydroxy-α-methyl-, (S)-Betuligenold-BetuligenolFrambinolNSC 40514p-(3-Hydroxybutyl)phenolrac-RhododendrolRaspberry AlcoholRHODODENDROL [INCI]Rhododenol

Synopsis

Rhododendrol: A Comprehensive Reference Article

1. Identity, Chemistry, and Natural Sources

1.1 Names and Chemical Identity

Rhododendrol (RD), also called 4-[(3R)-3-hydroxybutyl]phenol (systemic name), is an organic compound with the formula C₁₀H₁₄O₂. Its synonyms include 4-[(3R)-3-Hydroxybutyl]phenol, benzenepropanol 4-hydroxy-α-methyl-, 4-(3-hydroxybutyl)phenol, 4-(p-hydroxyphenyl)-2-butanol, and 2-butanol, 4-(p-hydroxyphenyl)-, with the IUPAC name 4-[(3R)-3-hydroxybutyl]phenol. It is also known by the synonyms betuligenol and frambinol, and carries CAS Numbers 501-96-2 (for the (R)-enantiomer) and 69617-84-1 (for the racemate).

Chemically, rhododendrol is a phenolic compound characterized by a hydroxyl group attached to a benzene ring, which contributes to its biological activity. Its molecular weight is 166.22, with the molecular formula C₁₀H₁₄O₂, and it presents as a white to almost-white powder or crystal in pure form. The molecule has a para-substituted structure and one chiral center. RD is a naturally occurring substance with two enantiomers, (R)-RD and (S)-RD.

1.2 Botanical Sources

Rhododendrol is a naturally occurring ingredient present in many plants, such as the Rhododendron. It occurs as the glucoside rhododendrin in leaves of the Rhododendron (Ericaceae), and it naturally occurs as a phenolic compound in plants such as Acer nikoense, Betula platyphylla, and the Chinese red birch Betula alba. The two enantiomers were found to be present in Rhododendron chrysanthum and Rhododendron maximum L. One commercially important botanical source is Rhododendron pentanthera, from which the compound has been isolated and purified.

Rhododendrol is produced in the inner bark of stressed and dying branches of most white-barked birch species by natural hydrolysis of the glucoside rhododendrin. Rhododendrin (as rhododendrol) was identified in hydrolyzed bark of 14 species of birch. A chemical investigation of the inner bark of Betula pubescens led to the isolation of rhododendrin, epirhododendrin, apiosylrhododendrin, and apiosylepirhododendrin, with the observation of both (+)- and (−)-rhododendrol glycosides occurring in the same species. Rhododendrin was found in the inner bark of many Betula (birch) species, and it was naturally hydrolyzed to rhododendrol when trees or branches were under drought stress.

Rhododendrin (bitter) and rhododendrol (tasteless) had first been isolated in 1901 in studies of the diuretic and diaphoretic properties of the leaves of Rhododendron chrysanthum. Later work on the bark of Betula alba (B. pendula) revealed similar substances called "betuloside" and "betuligenol," but subsequent work on the bark of B. platyphylla showed that the compounds from rhododendron and birch were chemically identical. Rhododendrol was determined to be 4-(p-hydroxyphenyl)-butan-2-ol and rhododendrin was the glucoside of this phenolic alcohol.

1.3 Common Forms and Preparations

The phenolic compound was first developed in 2010 as a tyrosinase inhibitor for skin-lightening cosmetics. A cosmetic product containing 2% 4-(p-hydroxyphenyl)-2-butanol (rhododendrol; RD), an active ingredient developed in 2008 and approved by the Ministry of Health, Labor, and Welfare under Japan's Pharmaceutical Affairs Law, was recalled in 2013 for causing leukoderma after having been sold on the Japanese market for 5 years. In cosmetic and research settings, the compound is encountered as a purified crystalline solid or in solution. Rhododendrol is typically synthesized through a series of chemical reactions starting with the precursor p-hydroxybenzaldehyde; this compound undergoes a series of steps, including reduction and alkylation, to produce the final product, 4-(p-hydroxyphenyl)butan-2-ol. The synthetic process ensures high purity of the ingredient.

2. Traditional and Historical Use

2.1 The Genus Rhododendron in Traditional Medicine

The first written reference to the Rhododendron species dates as far back as 401 B.C. The vast genus includes species that have been used in traditional medicine for the treatment of inflammatory conditions, pain, gastro-intestinal disorders, common cold, asthma, and skin disease. Despite their toxicity, rhododendrons have been used in ancient medical systems such as traditional Chinese and Ayurvedic medicine and also in European and North American folk medicine.

In China, approximately 25 species of Rhododendron are used as traditional medicines or folk remedies to treat various diseases, of which R. molle (NaoYangHua) has the longest medicinal use history and has been documented in the Chinese Pharmacopoeia 2020 Edition for the treatment of rheumatic arthralgia and pain. The medicinal records of R. molle can be traced back to the Han Dynasty. Rhododendron is used traditionally in Far-West Nepal as a remedy for many diseases and is preferred for its diverse medicinal properties with low side-effect profile. Flowers of this plant are traditionally utilized by the people residing in mountainous regions to make pickle, juice, jam, syrup, honey, and squash, and to treat various ailments like diarrhea, headache, inflammation, and bacterial and fungal infections.

Historically, parts of Rhododendron plants have been valued in traditional herbal medicine across Asia, particularly in Japanese, Chinese, and Himalayan folk remedies. While the isolated compound rhododendrol itself is a more recent discovery, extracts from Rhododendron species containing rhododendrol have long been used for their purported health-promoting properties. In traditional practices, Rhododendron extracts have been used to address issues such as inflammation, respiratory ailments, and skin conditions. Folk remedies often employed infusions, tinctures, or topical preparations to alleviate symptoms of rheumatism, reduce swelling, and promote overall wellness.

2.2 Rhododendrin (the Glucoside Precursor) and Traditional Diuretic Use

Betuloside or rhododendrin is an arylbutanoid glycoside and phenylpropanoid, meaning the sugar group is linked to a phenol. Rhododendrin (bitter) and rhododendrol (tasteless) had first been isolated in 1901 in studies of the diuretic and diaphoretic properties of the leaves of Rhododendron chrysanthum. The glycoside is produced in response to damage through grazing by hares and bark-boring insects as a protective chemical. This sugar has reported analgesic, anti-inflammatory, and diuretic benefits.

Important caution: the traditional use literature primarily documents preparations and extracts of the Rhododendron or Betula plants as a whole, not rhododendrol as an isolated phytochemical. The earliest known isolation of the compound itself dates to 1901, and its development as a purified cosmetic ingredient did not occur until the late 2000s. Traditional claims therefore apply to whole-plant preparations or to rhododendrin, the glycoside, rather than to isolated rhododendrol.

3. Key Constituents, Related Compounds, and Structure

The oxidation of racemic RD by mushroom tyrosinase rapidly produces RD-quinone, which gives rise to secondary quinone products. Human tyrosinase is able to oxidize both enantiomers of RD. Research into the phytochemistry of source plants has identified a number of co-occurring compounds.

Rhododendrol (free aglycone): An organic compound with the formula C₁₀H₁₄O₂, existing as two enantiomers, (R) and (S).
Rhododendrin: The glucoside form of rhododendrol, co-occurring with (−)-rhododendrol, avicularin, and hyperoside in the leaves of Rhododendron aureum.
Epirhododendrin: An epimeric glycoside isolated from the inner bark of Betula pubescens alongside rhododendrin.
RD-quinone and RD-cyclic quinone (2-methylchromane-6,7-dione): Metabolites produced when rhododendrol is oxidized by tyrosinase; RD-quinone is quickly converted to 2-methylchromane-6,7-dione (RD-cyclic quinone) and RD-hydroxy-p-quinone through cyclization and addition of a water molecule. RD-quinone and RD-cyclic quinone can be identified as RD-catechol and RD-cyclic catechol after NaBH₄ reduction.
RD-pheomelanin: Formed in melanoma cells exposed to RD, along with protein-SH adducts of RD-quinone.
RD-eumelanin: An oxidation product of RD that exhibits potent pro-oxidant activity enhanced by ultraviolet-A radiation.

In the past 13 years, a total of 610 chemical constituents were reported in Rhododendron plants overall, including 222 diterpenoids, 122 triterpenoids, 103 meroterpenoids, 71 flavonoids, 21 lignans, 1 phenylpropanoid, 22 phenolic acids, 25 sesquiterpenoids, 8 monoterpenoids, 11 coumarins, and 4 minor components. Rhododendrol is therefore one compound within a complex phytochemical matrix.

4. Mechanisms of Action

4.1 Tyrosinase Inhibition (Primary Mechanism)

Rhododendrol suppresses melanin biosynthesis, and the mechanism is shown to be due to its competitive inhibition of tyrosinase activity. When rhododendrol was added to cultured human melanocytes, cellular tyrosinase activity was dose-dependently suppressed with an IC₅₀ value of 5.3 μM. A Lineweaver–Burk plot analysis showed that rhododendrol inhibited mushroom tyrosinase competitively.

Rhododendrol adds a clinically relevant twist to this chemistry. Although it is a monophenol, rhododendrol serves as a substrate for human tyrosinase, where it is oxidized into a catechol intermediate, which then undergoes further oxidation to an ortho-quinone. This dual role — as both a competitive inhibitor and a tyrosinase substrate — is central to both its intended skin-lightening action and its observed toxicity.

4.2 Toxic Metabolite Formation

Oxidation of RD with mushroom tyrosinase rapidly produced RD-quinone, which was quickly converted to 2-methylchromane-6,7-dione (RD-cyclic quinone) and RD-hydroxy-p-quinone through cyclization and addition of a water molecule, respectively. Autoxidation of RD-cyclic catechol produced superoxide radical. RD-quinone and RD-cyclic quinone quantitatively bound to thiols such as cysteine and GSH. The melanocyte toxicity of RD is caused by its tyrosinase-catalyzed oxidation through production of RD-cyclic quinone, which depletes cytosolic glutathione and then binds to essential cellular proteins through their sulfhydryl groups. The production of reactive oxygen species (ROS) through autoxidation of RD-cyclic catechol may augment the toxicity.

4.3 Melanocyte Cytotoxicity and Apoptosis

Rhododendrol competitively inhibited mushroom tyrosinase and served as a good substrate, while it also showed cytotoxicity against cultured human melanocytes at high concentrations sufficient for inhibiting tyrosinase. The cytotoxicity was abolished by phenylthiourea, a chelator of the copper ions at the active site, and by specific knockdown of tyrosinase with siRNA. Hence, the cytotoxicity appeared to be triggered by the enzymatic conversion of rhododendrol to active products.

No reactive oxygen species were detected in the treated melanocytes, but up-regulation of the CCAAT-enhancer-binding protein homologous protein gene responsible for apoptosis and/or autophagy and caspase-3 activation were found to be tyrosinase-dependent. Melanocyte toxicity induces apoptosis of the cell, causing the melanocytes to die. This is due to an increased expression of caspase-3 and caspase-8. Caspase proteins are crucial mediators of apoptosis, with caspase-3 and caspase-8 being death proteases. Considering melanocytes are responsible for skin colour, apoptosis of these cells causes the colour of the skin to vanish.

4.4 Analgesic and Anti-inflammatory Activity of Rhododendrin (Glycoside Precursor)

Rhododendrin, the main compound of the BuOH fraction of Rhododendron aureum, exhibited significant analgesic actions in mice and anti-inflammatory actions in rats, assessed using writhing assays and vascular permeability assays for analgesic action, and carrageenan-induced paw edema and TPA-induced ear edema assays for anti-inflammatory action. These results suggest that rhododendrin is the major biologically active substance in the leaves of R. aureum with analgesic/anti-inflammatory activity. These findings pertain to rhododendrin (the glycoside form), not to free rhododendrol itself, and are based on animal models only.

5. Scientific Evidence by Area of Application

5.1 Skin Lightening and Hyperpigmentation

Background and Intended Use: Rhododendrol, an inhibitor of melanin synthesis, was developed for lightening/whitening cosmetics and was recently reported to induce a depigmentary disorder principally at the sites of repeated chemical contact.

Preclinical Evidence: Rhododendrol suppressed cellular tyrosinase activity in cultured human melanocytes as well as melanin synthesis in mouse B16 melanoma cells. Cellular tyrosinase activity was dose-dependently suppressed with an IC₅₀ value of 5.3 μM in cultured human melanocytes.

Human Evidence — Cosmetic Application: A cosmetic product containing 2% rhododendrol, an active ingredient approved by the Japanese Ministry of Health, Labor, and Welfare under Japan's Pharmaceutical Affairs Law, was sold on the Japanese market for approximately five years before its 2013 recall. In 2013, after rhododendrol reportedly caused skin depigmentation in consumers using RD-containing skin-brightening cosmetics, the cosmetics were withdrawn from the market.

Evidence Strength: The skin-lightening efficacy of rhododendrol at 2% concentration in cosmetic formulations was sufficient for regulatory approval in Japan, but the evidence base was primarily preclinical (cell-based) combined with observed field use. No randomized controlled clinical trials of skin-lightening efficacy have been identified in the peer-reviewed literature for rhododendrol specifically. Given the withdrawal of the compound from the market due to serious adverse effects, clinical development has not continued in this indication.

5.2 Rhododendrol-Induced Leukoderma (RDL) — Clinical Evidence

In July 2013, the marketing authorization holder (Kanebo Cosmetics Inc.) issued a voluntary recall globally. In a survey conducted by the marketing authorization holder, 19,606 individuals developed symptoms as of November 30, 2020, including 11,919 individuals who completely or almost completely recovered. Individuals who used skin-whitening cosmetics (quasi-drugs) containing 2% rhododendrol-containing agents developed leukoderma at a higher frequency than those who used other skin-whitening cosmetics.

The Japan Dermatological Association established the Special Committee on the Safety of Cosmetics Containing Rhododenol on July 17, 2013. The committee undertook activities to ascertain the condition of rhododendrol-induced leukoderma (RDL) to provide accurate information to medical professionals and patients, to investigate the pathology, and to establish diagnostic and treatment methods at the earliest possible stage.

Histopathological analysis of specimens of RDL-affected skin showed pigmentary incontinence and residual melanocytes, unlike the phenotypically similar disorder, vitiligo. Epidermal keratinocytes did not display notable abnormalities upon optical microscopic observation, whereas electron microscopic observation revealed residual melanocytes with degenerative melanosomes in the leukoderma lesions as a feature specific to RDL. Infiltration of CD4+ and CD8+ T cells was also observed in immunohistochemical analysis; however, unlike in vitiligo, CD8+ T cells were not dominant, suggesting the involvement of an immune response different from that associated with vitiligo.

Research found that only approximately 2.4% of users of RD-containing cosmetics developed leukoderma, while approximately 98% of users did not develop the condition. This suggests individual susceptibility factors (genetic, enzymatic, or immunological) play a significant role in determining who develops RDL.

According to the third nationwide survey conducted 18 months after the voluntary recall, patients whose conditions had completely healed, almost healed, or had improved accounted for more than 80% of cases of RDL.

5.3 Analgesic and Anti-inflammatory Activity (Preclinical)

Four compounds were isolated from the active fraction of Rhododendron aureum leaves and identified as (−)-rhododendrol, (−)-rhododendrin, avicularin, and hyperoside by spectroscopic methods. Rhododendrin, the main compound, exhibited significant analgesic actions in mice and anti-inflammatory actions in rats, accounting for 3.1% of the methanol extract and 0.48% of dried leaves on HPLC analysis. These results suggest that rhododendrin is the major biologically active substance with analgesic/anti-inflammatory activity in the leaves of R. aureum.

It is important to note that these pharmacological findings apply to rhododendrin (the glucoside) rather than to free rhododendrol, and all evidence remains at the preclinical (animal model) stage. No human clinical trials for analgesic or anti-inflammatory applications of rhododendrol have been identified.

5.4 Antioxidant Activity (Preclinical)

Research on Rhododendron species broadly demonstrates antioxidant activity in vitro, but this research pertains to extracts containing complex polyphenolic mixtures. Phytochemical studies on the genus established the presence of many biologically active secondary metabolites, including flavonoids, coumarins, terpenes, and sterols. Many were isolated and subjected to biological studies in which they exerted various kinds of pharmacological activities. Among them, anti-inflammatory, antioxidant, anti-HIV, antidiabetic, and anticancer potential were observed. However, no studies specifically isolating and testing rhododendrol for antioxidant effects in human subjects have been identified.

5.5 Adipogenesis and Metabolic Effects (Preclinical)

Rhododendrol is a natural phenolic compound that has been reported to prevent high-fat diet-induced elevation in body weight and to increase lipolysis in white adipocytes in male mice. This finding is based on animal model data and has not been confirmed in human clinical trials. The evidence is therefore preliminary and insufficient to draw any conclusions about efficacy in humans.

5.6 Hair Growth (Preclinical)

RD has shown potential to increase dermal IGF-I production through sensory neuron activation, promoting hair growth and increasing skin elasticity in preclinical research. Again, this finding is from preclinical data only, and no human clinical evidence has been identified for this application.

6. Body Systems Associated with Rhododendrol

Integumentary system (skin and pigmentation): The primary and most extensively studied association. Rhododendrol exerts melanocyte cytotoxicity via a tyrosinase-dependent mechanism, which underpins both its intended skin-lightening use and its documented adverse effect of inducing leukoderma.
Immune system: There is a raised possibility that RD-damaged melanocytes are attacked by the cellular immune system or that debris of damaged melanocytes can be recognized by local antigen-presenting cells to induce cytotoxic T lymphocytes for auto-antigens.
Musculoskeletal and pain pathways (glycoside precursor): The Rhododendron genus includes species used in traditional medicine for the treatment of inflammatory conditions and pain. Preclinical data support analgesic and anti-inflammatory activity for rhododendrin in animal models.
Adipose tissue and metabolism (preclinical): Rhododendrol has been reported to prevent high-fat diet-induced elevation in body weight and to increase lipolysis in white adipocytes in male mice at a preclinical level.

7. Dosage Forms and Dosages Reported in Scientific Sources

The following dosages and concentrations are reported in scientific literature only; they are presented as documented findings and do not represent recommendations.

Cosmetic topical (human, historical): Skin-whitening cosmetics (quasi-drugs) containing 2% rhododendrol-containing agents were the products associated with leukoderma development in Japanese consumers.
In vitro (cultured human melanocytes): When added to cultured human melanocytes, cellular tyrosinase activity was dose-dependently suppressed with an IC₅₀ value of 5.3 μM. Rhododendrol also inhibited melanin synthesis of mouse B16 melanoma cells at the same range of concentrations.
In vitro (cytotoxicity threshold): Rhododendrol showed cytotoxicity against cultured human melanocytes at high concentrations sufficient for inhibiting tyrosinase.
In vitro (B16 melanoma cells): Using specific indicators, moderate levels of RD-pheomelanin were detected in B16F1 cells exposed to 0.3 to 0.5 mM RD for 72 hours.
Animal (rhododendrin, not rhododendrol): Analgesic and anti-inflammatory studies used rhododendrin isolated from plant extracts in standard rodent models (writhing, paw edema assays); specific mg/kg doses are not reported in the accessible abstracts reviewed.

No oral supplementation dosages for rhododendrol in human subjects have been identified in the peer-reviewed literature.

8. Safety Considerations and Notable Adverse Effects

8.1 Rhododendrol-Induced Leukoderma (RDL) — The Major Safety Event

In 2013, after rhododendrol reportedly caused skin depigmentation in consumers using RD-containing skin-brightening cosmetics, the cosmetics were withdrawn from the market. The skin condition caused by RD is called RD-induced leukoderma.

In July 2013, cosmetics containing RD were recalled by that company because a considerable number of consumers developed leukoderma on their face, neck, and hands. Among an estimated 800,000 users of RD, 19,605 subjects (as of October 2016) reported that they developed leukoderma.

This rhododendrol-induced depigmentation can be either long-term or short-term. In most cases, repigmentation and cessation of further depigmentation occur after discontinuing exposure to the substance. However, some patients develop vitiligo vulgaris through the spread of depigmentation into non-exposed areas. This only occurs after severe chemical damage.

8.2 Biochemical Mechanism of Toxicity

The melanocyte toxicity of RD is caused by its tyrosinase-catalyzed oxidation through production of RD-cyclic quinone, which depletes cytosolic glutathione and then binds to essential cellular proteins through their sulfhydryl groups. The production of reactive oxygen species through autoxidation of RD-cyclic catechol may augment the toxicity.

RD-quinone binds covalently to non-protein thiols and proteins through cysteinyl residues. The covalent binding of RD-quinone to proteins was 20- to 30-fold greater than that of dopaquinone.

RD-eumelanin — an oxidation product of RD — exhibits potent pro-oxidant activity that is enhanced by ultraviolet-A radiation. This finding is relevant because ultraviolet exposure may have exacerbated adverse effects in consumers applying the cosmetics to sun-exposed skin.

8.3 Immune Involvement

The frequencies of CD8+ T cells in both lesional skin and peripheral blood are significantly higher in RD leukoderma patients as well as non-segmental vitiligo patients than in normal controls. One of the features of RDL is that inflammatory cells infiltrating the RDL area are predominantly CD4+ T cells rather than CD8+ T cells; these cells are relatively dense and are detected in the upper layer of the dermis.

8.4 Selective Risk: Why Not All Users Were Affected

Research considered the factors underlying why only 2.4% of users developed the condition. Approximately 98% of users of RD-containing cosmetics did not develop leukoderma. The precise individual susceptibility factors — potentially including variation in tyrosinase activity, melanocyte density, immunogenetic background, or glutathione levels — remain an active area of investigation but have not yet been definitively characterized.

8.5 Regulatory Responses

On July 5, 2013, Kanebo notified the China Food and Drug Administration (CFDA) of the recall of some whitening cosmetics containing rhododendrol (CAS: 69617-84-1). The CFDA verified that Kanebo had previously submitted an application for new cosmetic ingredient approval for rhododendrol; however, the ingredient did not pass safety assessment and no cosmetics containing rhododendrol were ever approved by CFDA. The Taiwan FDA independently acted: after extensive research into rhododendrol, it banned its use in cosmetic products.

8.6 Toxicity of the Rhododendron Genus (Contextual)

Rhododendrons are well known for their toxicity, and some species have been traditionally used as poison. The toxicity of the genus is due to grayanotoxins, diterpenes which activate voltage-gated sodium channels. These toxic alkaloids are structurally and pharmacologically distinct from rhododendrol (a phenolic compound), but their presence in the same plant genus is relevant context for any use of whole-plant preparations.

9. Summary of Evidence Quality

The scientific literature on rhododendrol is dominated by research into its adverse effects (RDL) following the 2013 Kanebo recall. The mechanistic evidence for tyrosinase inhibition and cytotoxicity is well-characterized at the biochemical and cell-culture level. Analgesic and anti-inflammatory effects have been demonstrated for the related compound rhododendrin in animal models. Evidence for systemic health benefits (metabolism, hair growth) is limited to preliminary preclinical observations. No peer-reviewed randomized controlled clinical trials for any health benefit have been identified for isolated rhododendrol in humans. The safety data from the 2013 public health event are extensive and represent the most robust human evidence available — demonstrating that topical application at 2% concentration carried a documented risk of leukoderma in a susceptible subpopulation.

References

Health Conditions

Health conditions that Rhododendrol may help support.

No conditions available.

Body Systems

Body systems that Rhododendrol may help support.

No body systems available.